Intra Cellular Therapies reported $-87923000 in EBIT for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Acadia Pharmaceuticals ACAD:US $ -33651000 79.36M
ALKERMES ALKS:US -34457000 7.87M
Aptinyx Inc APTX:US $ -17105000 2.27M
Biocryst Pharmaceuticals BCRX:US $ -34722000 15.24M
Biogen BIIB:US $ 940.9M 409.4M
Bristol Myers Squibb BMY:US $ 3197M 9M
Cytokinetics CYTK:US $ -10874000 66.98M
Esperion Therapeutics ESPR:US $ -52376000 9.39M
Gilead Sciences GILD:US $ 2029M 868M
Halozyme Therapeutics HALO:US $ 34.06M 41.61M
Intra Cellular Therapies ITCI:US $ -87923000 15.26M
JAZZ PHA JAZZ:US 126.35M 38.8M
Johnson & Johnson JNJ:US $ 6941M 599M
Marinus Pharmaceuticals MRNS:US -36766000 20.06M
Minerva Neurosciences NERV:US $ -6965190 1.02M
Nektar Therapeutics NKTR:US $ -47713000 67.37M
Neurocrine Biosciences NBIX:US $ 54.7M 51.6M
Novartis NVS:US 3.32B 176M
Prothena PRTA:US -43209000 5.26M
Redhill Biopharma RDHL:US -13238000 1.44M
Supernus Pharmaceuticals SUPN:US $ 11.35M 9.38M
United Therapeutics UTHR:US $ 201.8M 86.2M